

Your membership matters.

Continue to help lead the fight against kidney disease. Renew today.

www.asn-online.org/membership



CJASN Clinical Journal of the American Society of Nephrology

[HOME](#) | [CURRENT ISSUE](#) | [ADVERTISE](#) | [SUBSCRIBE](#) | [ARCHIVES](#) | [FEEDBACK](#) | [ALERTS](#) | [HELP](#)

User Name

Password

[LOG-IN](#)

Search

[Go](#)

Advanced Search

Update on Lupus Nephritis



[« Previous](#) | [Next Article »](#)
[Table of Contents](#)

Salem Almaani, Alexa Meara, Brad H. Rovin

[+](#) Author Affiliations

Correspondence:

Dr. Brad H. Rovin, Nephrology Division, Ohio State University Wexner Medical, Ground Floor, 395 West 12th Avenue, Columbus, OH 43201. Email: Rovin.1@osu.edu

Abstract

SLE is a chronic inflammatory disease that affects the kidneys in about 50% of patients. Lupus nephritis is a major risk factor for overall morbidity and mortality in SLE, and despite potent anti-inflammatory and immunosuppressive therapies still ends in CKD or ESRD for too many patients. This review highlights recent updates in our understanding of disease epidemiology, genetics, pathogenesis, and treatment in an effort to establish a framework for lupus nephritis management that is patient-specific and oriented toward maintaining long-term kidney function in patients with lupus.

systemic lupus erythematosus Epidemiology and outcomes
glomerular disease glomerulonephritis immunosuppression
nephritis humans kidney kidney failure chronic
Lupus Erythematosus Discoid Lupus Erythematosus Systemic
lupus nephritis Renal Insufficiency Chronic risk factors

Copyright © 2017 by the American Society of Nephrology

We recommend

Update on Lupus Nephritis A Systematic Review and Meta-analysis

Salem Almaani et al., *Clin J Am Soc Nephrol*

Current and Emerging Therapies for Lupus Nephritis

Samir V. Parikh et al., *J Am Soc Nephrol*

Calcineurin Inhibitors in the Treatment of Lupus Nephritis: A Hare Versus Turtle Story?

Isabelle Ayoub et al., *J Am Soc Nephrol*

Can we personalize treatment for kidney diseases?

Brad H Rovin et al., *Clin J Am Soc Nephrol*

Clinical-Morphological Features and Outcomes of Lupus Podocytopathy.

Weixin Hu et al., *Clin J Am Soc Nephrol*

Systemic lupus erythematosus [🔗](#)

DermNet NZ

MP1: CORRECTING ATHEROGENIC EFFECTS OF LUPUS PLASMA ON MACROPHAGES WITH RESVERATROL AND MYCOPHENOLATE [🔗](#)

NM Siegart et al., *J Investig Med*

Presentation, pathology and prognosis of renal disease in type 2 diabetes [🔗](#)

Jasmine Tan et al., *BMJ Open Diab Res Care*

Hydroxychloroquine in patients with systemic lupus erythematosus with end-stage renal disease [🔗](#)

Laura D Carbone et al., *J Investig Med*

Case Study: New-Onset Diabetes After Renal Transplantation [🔗](#)

Warren Clayton et al., *Clin Diabetes*

This Article

Published online before print November 2016, doi: 10.2215/CJN.05780616
CJASN May 08, 2017 vol. 12 no. 5 825-835

Free Access

» Abstract *Free*

Figures Only *Free*

Full Text *Free*

Full Text (PDF) *Free*

Article Usage Stats

Article Usage Statistics

Services

Email this article to a colleague

Alert me when this article is cited

Alert me if a correction is posted

Similar articles in this journal

Similar articles in PubMed

Download to citation manager

[🔗 Get Permissions](#)

[Citing Articles](#)

[Google Scholar](#)

[PubMed](#)

Current Issue

March 07, 2018, 13 (3)



Alert me to new issues of CJASN

ONLINE SUBMISSION

AUTHOR RESOURCES

ABOUT CJASN

EDITORIAL BOARD

REPRINTS / PERMISSIONS

IMPACT FACTOR

MOST READ

MOST CITED

CJASN ePress

Updated on:
March 9, 2018
By Date / By Subject



Advertising Disclaimer



ASN members enjoy discounts on ASN's educational programs, subscriptions to ASN's publications, and more.

Join or renew today at www.asn-online.org/membership

